Key Takeaway: Cellectis has released its monthly information regarding share capital and voting rights, as of September 3, 2026. The announcement includes details pertinent to its listing on Euronext Growth and provides contact information for media and investor relations. This update is part of the company's ongoing communication with stakeholders.
Price reaction · baseline $3.32 (2026-09-03 close) · hit after-hours · clean, no other CLLS news in the window
day 0 close
-2.4%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
7.7%
average across 3 past catalysts
Lead asset
UCART22
Phase 1 · B-cell Acute Lymphoblastic Leukemia
Full Press Release Details
PARIS, Sept. 03, 2026 (GLOBE NEWSWIRE) --
Listing market: Euronext Growth
ISIN code: FR0010425595
For further information on Cellectis, please contact:
Media contacts: Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93 Investor Relations contact: Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com
Attachment
• Voting_Rights_PR_August_2026_EN
Frequently Asked Questions
What is the date of the Cellectis update?
The update was released on September 3, 2026.
Where is Cellectis listed?
Cellectis is listed on Euronext Growth.
Who can be contacted for media inquiries?
Pascalyne Wilson is the media contact for inquiries.